Agency Forms Undergoing Paperwork Reduction Act Review, 38694-38696 [2018-16797]

Download as PDF 38694 Federal Register / Vol. 83, No. 152 / Tuesday, August 7, 2018 / Notices charged with the duty of winding up the affairs of the former institutions and liquidating all related assets. The Receiver has fulfilled its obligations and made all dividend distributions required by law. NOTICE OF TERMINATION OF RECEIVERSHIPS Fund 10035 10225 10285 10460 10482 Receivership name ................................................. ................................................. ................................................. ................................................. ................................................. City Alliance Bank ..................................... BC National Banks ............................ Sonoma Valley Bank ......................... Excel Bank ......................................... 1st Commerce Bank .......................... Culver City ......................................... Butler ................................................. Sonoma ............................................. Sedalia ............................................... North Las Vegas ................................ The Receiver has further irrevocably authorized and appointed FDICCorporate as its attorney-in-fact to execute and file any and all documents that may be required to be executed by the Receiver which FDIC-Corporate, in its sole discretion, deems necessary, including but not limited to releases, discharges, satisfactions, endorsements, assignments, and deeds. Effective on the termination dates listed above, the Receiverships have been terminated, the Receiver has been discharged, and the Receiverships have ceased to exist as legal entities. Dated at Washington, DC, on August 2, 2018. Federal Deposit Insurance Corporation. Robert E. Feldman, Executive Secretary. [FR Doc. 2018–16832 Filed 8–6–18; 8:45 am] BILLING CODE 6714–01–P FEDERAL RESERVE SYSTEM daltland on DSKBBV9HB2PROD with NOTICES Formations of, Acquisitions by, and Mergers of Bank Holding Companies The companies listed in this notice have applied to the Board for approval, pursuant to the Bank Holding Company Act of 1956 (12 U.S.C. 1841 et seq.) (BHC Act), Regulation Y (12 CFR part 225), and all other applicable statutes and regulations to become a bank holding company and/or to acquire the assets or the ownership of, control of, or the power to vote shares of a bank or bank holding company and all of the banks and nonbanking companies owned by the bank holding company, including the companies listed below. The applications listed below, as well as other related filings required by the Board, are available for immediate inspection at the Federal Reserve Bank indicated. The applications will also be available for inspection at the offices of the Board of Governors. Interested persons may express their views in writing on the standards enumerated in the BHC Act (12 U.S.C. 1842(c)). If the proposal also involves the acquisition of VerDate Sep<11>2014 16:54 Aug 06, 2018 Jkt 244001 a nonbanking company, the review also includes whether the acquisition of the nonbanking company complies with the standards in section 4 of the BHC Act (12 U.S.C. 1843). Unless otherwise noted, nonbanking activities will be conducted throughout the United States. Unless otherwise noted, comments regarding each of these applications must be received at the Reserve Bank indicated or the offices of the Board of Governors not later than September 4, 2018. A. Federal Reserve Bank of Chicago (Colette A. Fried, Assistant Vice President) 230 South LaSalle Street, Chicago, Illinois 60690–1414: 1. First Mid-Illinois Bancshares, Inc., Mattoon, Illinois; to acquire 100 percent of SCB Bancorp, Inc., and thereby indirectly acquire Soy Capital Bank and Trust Company, both of Decatur, Illinois. B. Federal Reserve Bank of Minneapolis (Mark A. Rauzi, Vice President), 90 Hennepin Avenue, Minneapolis, Minnesota 55480–0291: 1. Park Financial Group, Inc., Minneapolis, Minnesota; to acquire 48.46 percent of Mesaba Bancshares, Inc., Grand Rapids, Minnesota; and thereby indirectly acquire The Lake Bank, Two Harbors, Minnesota, and American Bank of the North, Nashwauk, Minnesota. In addition, Park Financial Group, Inc., has acquired an option to purchase the remaining 51.54 percent of the voting shares of Mesaba Bancshares, Inc., Grand Rapids, Minnesota. Board of Governors of the Federal Reserve System, August 2, 2018. Yao-Chin Chao, Assistant Secretary of the Board. [FR Doc. 2018–16872 Filed 8–6–18; 8:45 am] BILLING CODE 6210–01–P PO 00000 Frm 00018 Fmt 4703 Sfmt 4703 State CA MO CA MO NV Termination date 8/1/2018 8/1/2018 8/1/2018 8/1/2018 8/1/2018 DEPARTMENT OF HEALTH AND HUMAN SERVICES Centers for Disease Control and Prevention [30Day–18–17BAN] Agency Forms Undergoing Paperwork Reduction Act Review In accordance with the Paperwork Reduction Act of 1995, the Centers for Disease Control and Prevention (CDC) has submitted the information collection request entitled Strengthening United States Response to Resistant Gonorrhea (SURRG) to the Office of Management and Budget (OMB) for review and approval. CDC previously published a ‘‘Proposed Data Collection Submitted for Public Comment and Recommendations’’ notice on November 15, 2017 to obtain comments from the public and affected agencies. CDC received one nonsubstantive comment on this 60 day public notice. This notice serves to allow an additional 30 days for public and affected agency comments. CDC will accept all comments for this proposed information collection project. The Office of Management and Budget is particularly interested in comments that: (a) Evaluate whether the proposed collection of information is necessary for the proper performance of the functions of the agency, including whether the information will have practical utility; (b) Evaluate the accuracy of the agencies estimate of the burden of the proposed collection of information, including the validity of the methodology and assumptions used; (c) Enhance the quality, utility, and clarity of the information to be collected; (d) Minimize the burden of the collection of information on those who are to respond, including, through the use of appropriate automated, electronic, mechanical, or other technological collection techniques or other forms of information technology, E:\FR\FM\07AUN1.SGM 07AUN1 Federal Register / Vol. 83, No. 152 / Tuesday, August 7, 2018 / Notices e.g., permitting electronic submission of responses; and (e) Assess information collection costs. To request additional information on the proposed project or to obtain a copy of the information collection plan and instruments, call (404) 639–7570 or send an email to omb@cdc.gov. Direct written comments and/or suggestions regarding the items contained in this notice to the Attention: CDC Desk Officer, Office of Management and Budget, 725 17th Street NW, Washington, DC 20503 or by fax to (202) 395–5806. Provide written comments within 30 days of notice publication. Proposed Project Strengthening U.S. Response to Resistant Gonorrhea (SURRG)—New— National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention (NCHHSTP), Centers for Disease Control and Prevention (CDC). daltland on DSKBBV9HB2PROD with NOTICES Background and Brief Description The purposes of Strengthening U.S. Response to Resistant Gonorrhea (SURRG) are to: (1) Improve national capacity to detect, monitor, and respond to emerging antibiotic-resistant gonorrhea, (2) understand trends in, and factors contributing to antibioticresistant gonorrhea, and (3) build a robust evidence base for public health action. This information collection is important because: (1) Effective treatment of gonorrhea is critical to gonorrhea control and prevention; (2) untreated or inadequately treated gonorrhea can cause serious reproductive health complications, such as infertility; (3) Neisseria gonorrhoeae (the bacterium that causes gonorrhea) has consistently demonstrated the ability to develop resistance to the antibiotics used for treatment and may be developing resistance to the last remaining treatment option recommended by the CDC; and (4) antibiotic-resistant gonorrhea is extremely difficult to detect without enhanced surveillance and public health activities, such as SURRG, because healthcare providers rarely perform or have access to resistance testing for individual patients. SURRG will support rapid detection of resistant gonorrhea and get actionable information into the hands of healthcare providers (to support appropriate treatment of individual patients) and local health departments (to support rapid public health response to slow the spread of resistant infections). VerDate Sep<11>2014 16:54 Aug 06, 2018 Jkt 244001 Jurisdictions participating in SURRG applied, as part of a competitive process, and will participate voluntarily. As an overview of SURRG, healthcare providers at participating clinics (sexually transmitted disease [STD] clinics affiliated with a single public health department or other participating non-STD clinic sites) will collect specimens for N. gonorrhoeae culture testing from men and women seeking care for possible gonorrhea. Specimens that demonstrate N. gonorrhoeae (called ‘‘isolates’’) will undergo antibiotic resistance testing within several days at the local public health laboratory. Laboratory results demonstrating resistance will be rapidly communicated by the laboratory to the healthcare provider and designated health department staff member, who will initiate a field investigation. Researchers will interview the patient (from whom the resistant specimen was collected) about risk factors and recent contacts, and will re-test to ensure cure. The health department will interview recent contacts and test them for gonorrhea. The participating health departments will collect and transmit to CDC, demographic and clinical data about persons tested for and diagnosed with gonorrhea in the participating clinics, results of local antibiotic resistance testing, and information about field investigations. None of the data transmitted to CDC will contain any personally identifiable information. CDC will use the data to monitor resistance, understand risk factors for resistance, and identify new approaches to prevent the spread of resistance. CDC will receive transmitted data through its Secure Access Management Services (SAMS). SAMS is an approved federal information technology system that provides authorized and validated users secure and encrypted access to CDC file transfer applications. The encrypted data will be stored in a secure CDC server with strictly controlled and restricted access rights. Isolates will be shipped each month to one of four Antibiotic Resistance Regional Laboratory Network (ARLN) laboratories for confirmatory antibiotic susceptibility testing and molecular characterization. Under the SURRG protocol, the local SURRG data managers from each of the funded jurisdictions will abstract STD clinic data for patients tested for gonorrhea, receive data from non-STD clinic healthcare sites about persons tested for gonorrhea, receive resistance testing laboratory results from local public health laboratories, abstract data about field investigations, and will PO 00000 Frm 00019 Fmt 4703 Sfmt 4703 38695 merge the data. Every two months, the local SURRG data manager will clean the data, remove personally identifiable information, and transmit the data to CDC. We estimate these data processes will take 16 hours every two months. Annually, the local SURRG data manager will send a final cumulative data file. Seven data transmissions/ responses will occur. Every two months, data managers at each of the participating non-STD clinic health centers will abstract and clean data and securely transmit the data to the local SURRG data manager. We estimate that it will take 3 hours each time data managers at each non-STD SURRG location abstract, clean, and transmit SURRG data. Microbiologists at public health laboratories from each of the nine SURRG funded jurisdictions will conduct antibiotic resistance testing on all N. gonorrhoeae isolates from all STD clinic sites and non-STD clinic sites participating in SURRG. Each test takes approximately 10 minutes of staff time, and testing of control strains will also be conducted approximately twice per week at each laboratory. On average, each jurisdiction will conduct approximately 600 resistance tests per year for patient care, plus 100 control strains per year for quality assurance. Thus, each grantee will perform approximately 700 tests per year. Every two months, a laboratory data manager will abstract test results and securely send the data file to the local SURRG data manager. We estimate that laboratory data managers will spend approximately 1 hour each time they abstract, clean, and transmit project data. Health department staff will interview any person diagnosed with antibioticresistant gonorrhea or having a case of gonorrhea of public health significance index case, a diagnosed person’s social and sexual contacts, and the sexual contacts of the index case’s sexual contacts. On average, each jurisdiction will identify four drug-resistant isolates each month. These isolates will spur field investigations, which will result in six additional interviews each month. We estimate 120 interviews will occur annually at each site (annual 1,080 interviews for the nine sites). Each interview will take 30 minutes. The total estimated annual burden hours are 2,976. Respondents receive federal funds to participate in this project. There are no additional costs to respondents other than their time. E:\FR\FM\07AUN1.SGM 07AUN1 38696 Federal Register / Vol. 83, No. 152 / Tuesday, August 7, 2018 / Notices ESTIMATED ANNUALIZED BURDEN HOURS Number of respondents Number of responses per respondent Average burden per response (in hours) Type of respondents Form name Local SURRG data manager .......................... Data manager at non-STD clinic health centers. Public Health Laboratory Microbiologist ......... Public Health Laboratory Data Manager ........ Gonorrhea Patients, Social and Sexual Contacts. Facility, Laboratory and field Elements .......... Non-STD clinic Elements ............................... 9 18 7 6 16 3 Laboratory Testing ......................................... Laboratory Elements ...................................... Field Investigation Elements .......................... 9 9 1,080 700 6 1 10/60 1 30/60 Jeffrey M. Zirger, Acting Chief, Information Collection Review Office, Office of Scientific Integrity, Office of the Associate Director for Science, Office of the Director, Centers for Disease Control and Prevention. [FR Doc. 2018–16797 Filed 8–6–18; 8:45 am] BILLING CODE 4163–18–P Centers for Medicare & Medicaid Services Privacy Act of 1974; Matching Program Centers for Medicare & Medicaid Services, Department of Health and Human Services. ACTION: Notice of a new matching program. AGENCY: daltland on DSKBBV9HB2PROD with NOTICES Jkt 244001 If you have questions about the matching program, you may contact Jack Lavelle, Senior Advisor, Marketplace Eligibility and Enrollment Group, Centers for Consumer Information and Insurance Oversight, CMS, at (410) 786–0639, or by email at Jack.Lavelle1@cms.hhs.gov, or by mail at 7501 Wisconsin Ave., Bethesda, MD 20814. FOR FURTHER INFORMATION CONTACT: In accordance with the Privacy Act of 1974, as amended, the Department of Health and Human Services (HHS), Centers for Medicare & Medicaid Services (CMS) is providing notice of a re-established matching program between CMS and the Social Security Administration (SSA), ‘‘Determining Enrollment or Eligibility for Insurance Affordability Programs Under the Patient Protection and Affordable Care Act (ACA).’’ The matching program provides CMS with SSA data to use in determining individuals’ eligibility to enroll in a qualified health plan through an exchange established under the ACA and for insurance affordability programs and certificates of exemption, and to make eligibility redeterminations and renewals, including appeal determinations. DATES: The deadline for comments on this notice is September 6, 2018. The reestablished matching program will commence not sooner than 30 days after publication of this notice, provided no comments are received that warrant a change to this notice. The matching program will be conducted for an initial term of 18 months (from approximately SUMMARY: 16:54 Aug 06, 2018 Interested parties may submit written comments on this notice, by mail or email, to the CMS Privacy Officer, Division of Security, Privacy Policy & Governance, Information Security & Privacy Group, Office of Information Technology, Centers for Medicare & Medicaid Services, Location: N1–14–56, 7500 Security Blvd., Baltimore, MD 21244–1850, Walter.Stone@cms.hhs.gov. ADDRESSES: DEPARTMENT OF HEALTH AND HUMAN SERVICES VerDate Sep<11>2014 September 2018 to March 2020) and within 3 months of expiration may be renewed for one additional year if the parties make no change to the matching program and certify that the program has been conducted in compliance with the matching agreement. The Privacy Act of 1974, as amended (5 U.S.C. 552a) provides certain protections for individuals applying for and receiving Federal benefits. The law governs the use of computer matching by Federal agencies when records in a system of records (meaning, federal agency records about individuals retrieved by name or other personal identifier) are matched with records of other federal or non-federal agencies. The Privacy Act requires agencies involved in a matching program to: 1. Enter into a written agreement, which must be prepared in accordance with the Privacy Act, approved by the Data Integrity Board of each source and recipient Federal agency, provided to Congress and the Office of Management and Budget (OMB), and made available to the public, as required by 5 United States Code (U.S.C.) 552a(o), (u)(3)(A), and (u)(4). SUPPLEMENTARY INFORMATION: PO 00000 Frm 00020 Fmt 4703 Sfmt 4703 2. Notify the individuals whose information will be used in the matching program that the information they provide is subject to verification through matching, as required by 5 U.S.C. 552a(o)(1)(D). 3. Verify match findings before suspending, terminating, reducing, or making a final denial of an individual’s benefits or payments or taking other adverse action against the individual, as required by 5 U.S.C. 552a(p). 4. Report the matching program to Congress and the OMB, in advance and annually, as required by 5 U.S.C. 552a(o)(2)(A)(i), (r), and (u)(3)(D). 5. Publish advance notice of the matching program in the Federal Register as required by 5 U.S.C. 552a(e)(12). This matching program meets these requirements. Dated: August 1, 2018. Walter Stone, CMS Privacy Act Officer, Division of Security Privacy Policy and Governance, Information Security and Privacy Group, Office of Information Technology, Centers for Medicare & Medicaid Services. PARTICIPATING AGENCIES Department of Health and Human Services (HHS), Centers for Medicare & Medicaid Services (CMS) is the recipient agency, and the Social Security Administration (SSA) is the source agency. AUTHORITY FOR CONDUCTING THE MATCHING PROGRAM: The matching program is authorized under 42 U.S.C. 18001. PURPOSE(S): The purpose of the matching program is to provide CMS with SSA data that CMS needs to determine individuals’ eligibility to enroll in a qualified health plan through an exchange established under the ACA and for insurance affordability programs and certificates of exemption, and to make eligibility redetermination and renewal decisions, including appeal determinations. The E:\FR\FM\07AUN1.SGM 07AUN1

Agencies

[Federal Register Volume 83, Number 152 (Tuesday, August 7, 2018)]
[Notices]
[Pages 38694-38696]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2018-16797]


=======================================================================
-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

[30Day-18-17BAN]


Agency Forms Undergoing Paperwork Reduction Act Review

    In accordance with the Paperwork Reduction Act of 1995, the Centers 
for Disease Control and Prevention (CDC) has submitted the information 
collection request entitled Strengthening United States Response to 
Resistant Gonorrhea (SURRG) to the Office of Management and Budget 
(OMB) for review and approval. CDC previously published a ``Proposed 
Data Collection Submitted for Public Comment and Recommendations'' 
notice on November 15, 2017 to obtain comments from the public and 
affected agencies. CDC received one non-substantive comment on this 60 
day public notice. This notice serves to allow an additional 30 days 
for public and affected agency comments.
    CDC will accept all comments for this proposed information 
collection project. The Office of Management and Budget is particularly 
interested in comments that:
    (a) Evaluate whether the proposed collection of information is 
necessary for the proper performance of the functions of the agency, 
including whether the information will have practical utility;
    (b) Evaluate the accuracy of the agencies estimate of the burden of 
the proposed collection of information, including the validity of the 
methodology and assumptions used;
    (c) Enhance the quality, utility, and clarity of the information to 
be collected;
    (d) Minimize the burden of the collection of information on those 
who are to respond, including, through the use of appropriate 
automated, electronic, mechanical, or other technological collection 
techniques or other forms of information technology,

[[Page 38695]]

e.g., permitting electronic submission of responses; and
    (e) Assess information collection costs.
    To request additional information on the proposed project or to 
obtain a copy of the information collection plan and instruments, call 
(404) 639-7570 or send an email to [email protected]. Direct written comments 
and/or suggestions regarding the items contained in this notice to the 
Attention: CDC Desk Officer, Office of Management and Budget, 725 17th 
Street NW, Washington, DC 20503 or by fax to (202) 395-5806. Provide 
written comments within 30 days of notice publication.

Proposed Project

    Strengthening U.S. Response to Resistant Gonorrhea (SURRG)--New--
National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention 
(NCHHSTP), Centers for Disease Control and Prevention (CDC).

Background and Brief Description

    The purposes of Strengthening U.S. Response to Resistant Gonorrhea 
(SURRG) are to: (1) Improve national capacity to detect, monitor, and 
respond to emerging antibiotic-resistant gonorrhea, (2) understand 
trends in, and factors contributing to antibiotic-resistant gonorrhea, 
and (3) build a robust evidence base for public health action. This 
information collection is important because: (1) Effective treatment of 
gonorrhea is critical to gonorrhea control and prevention; (2) 
untreated or inadequately treated gonorrhea can cause serious 
reproductive health complications, such as infertility; (3) Neisseria 
gonorrhoeae (the bacterium that causes gonorrhea) has consistently 
demonstrated the ability to develop resistance to the antibiotics used 
for treatment and may be developing resistance to the last remaining 
treatment option recommended by the CDC; and (4) antibiotic-resistant 
gonorrhea is extremely difficult to detect without enhanced 
surveillance and public health activities, such as SURRG, because 
healthcare providers rarely perform or have access to resistance 
testing for individual patients.
    SURRG will support rapid detection of resistant gonorrhea and get 
actionable information into the hands of healthcare providers (to 
support appropriate treatment of individual patients) and local health 
departments (to support rapid public health response to slow the spread 
of resistant infections).
    Jurisdictions participating in SURRG applied, as part of a 
competitive process, and will participate voluntarily. As an overview 
of SURRG, healthcare providers at participating clinics (sexually 
transmitted disease [STD] clinics affiliated with a single public 
health department or other participating non-STD clinic sites) will 
collect specimens for N. gonorrhoeae culture testing from men and women 
seeking care for possible gonorrhea. Specimens that demonstrate N. 
gonorrhoeae (called ``isolates'') will undergo antibiotic resistance 
testing within several days at the local public health laboratory. 
Laboratory results demonstrating resistance will be rapidly 
communicated by the laboratory to the healthcare provider and 
designated health department staff member, who will initiate a field 
investigation. Researchers will interview the patient (from whom the 
resistant specimen was collected) about risk factors and recent 
contacts, and will re-test to ensure cure. The health department will 
interview recent contacts and test them for gonorrhea. The 
participating health departments will collect and transmit to CDC, 
demographic and clinical data about persons tested for and diagnosed 
with gonorrhea in the participating clinics, results of local 
antibiotic resistance testing, and information about field 
investigations. None of the data transmitted to CDC will contain any 
personally identifiable information. CDC will use the data to monitor 
resistance, understand risk factors for resistance, and identify new 
approaches to prevent the spread of resistance. CDC will receive 
transmitted data through its Secure Access Management Services (SAMS). 
SAMS is an approved federal information technology system that provides 
authorized and validated users secure and encrypted access to CDC file 
transfer applications. The encrypted data will be stored in a secure 
CDC server with strictly controlled and restricted access rights. 
Isolates will be shipped each month to one of four Antibiotic 
Resistance Regional Laboratory Network (ARLN) laboratories for 
confirmatory antibiotic susceptibility testing and molecular 
characterization.
    Under the SURRG protocol, the local SURRG data managers from each 
of the funded jurisdictions will abstract STD clinic data for patients 
tested for gonorrhea, receive data from non-STD clinic healthcare sites 
about persons tested for gonorrhea, receive resistance testing 
laboratory results from local public health laboratories, abstract data 
about field investigations, and will merge the data. Every two months, 
the local SURRG data manager will clean the data, remove personally 
identifiable information, and transmit the data to CDC. We estimate 
these data processes will take 16 hours every two months. Annually, the 
local SURRG data manager will send a final cumulative data file. Seven 
data transmissions/responses will occur.
    Every two months, data managers at each of the participating non-
STD clinic health centers will abstract and clean data and securely 
transmit the data to the local SURRG data manager. We estimate that it 
will take 3 hours each time data managers at each non-STD SURRG 
location abstract, clean, and transmit SURRG data.
    Microbiologists at public health laboratories from each of the nine 
SURRG funded jurisdictions will conduct antibiotic resistance testing 
on all N. gonorrhoeae isolates from all STD clinic sites and non-STD 
clinic sites participating in SURRG. Each test takes approximately 10 
minutes of staff time, and testing of control strains will also be 
conducted approximately twice per week at each laboratory. On average, 
each jurisdiction will conduct approximately 600 resistance tests per 
year for patient care, plus 100 control strains per year for quality 
assurance. Thus, each grantee will perform approximately 700 tests per 
year. Every two months, a laboratory data manager will abstract test 
results and securely send the data file to the local SURRG data 
manager. We estimate that laboratory data managers will spend 
approximately 1 hour each time they abstract, clean, and transmit 
project data.
    Health department staff will interview any person diagnosed with 
antibiotic-resistant gonorrhea or having a case of gonorrhea of public 
health significance index case, a diagnosed person's social and sexual 
contacts, and the sexual contacts of the index case's sexual contacts.
    On average, each jurisdiction will identify four drug-resistant 
isolates each month. These isolates will spur field investigations, 
which will result in six additional interviews each month. We estimate 
120 interviews will occur annually at each site (annual 1,080 
interviews for the nine sites). Each interview will take 30 minutes.
    The total estimated annual burden hours are 2,976. Respondents 
receive federal funds to participate in this project. There are no 
additional costs to respondents other than their time.

[[Page 38696]]



                                        Estimated Annualized Burden Hours
----------------------------------------------------------------------------------------------------------------
                                                                                     Number of    Average burden
          Type of respondents                   Form name            Number of     responses per   per response
                                                                    respondents     respondent      (in hours)
----------------------------------------------------------------------------------------------------------------
Local SURRG data manager..............  Facility, Laboratory and               9               7              16
                                         field Elements.
Data manager at non-STD clinic health   Non-STD clinic Elements.              18               6               3
 centers.
Public Health Laboratory                Laboratory Testing......               9             700           10/60
 Microbiologist.
Public Health Laboratory Data Manager.  Laboratory Elements.....               9               6               1
Gonorrhea Patients, Social and Sexual   Field Investigation                1,080               1           30/60
 Contacts.                               Elements.
----------------------------------------------------------------------------------------------------------------


Jeffrey M. Zirger,
Acting Chief, Information Collection Review Office, Office of 
Scientific Integrity, Office of the Associate Director for Science, 
Office of the Director, Centers for Disease Control and Prevention.
[FR Doc. 2018-16797 Filed 8-6-18; 8:45 am]
 BILLING CODE 4163-18-P
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.